Press Releases

AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials (SIROCCO and CALIMA), demonstrating significant reductions in the annual asthma exacerbation rate...

Otsuka Holdings Co Ltd announced the signing of a development and commercialization agreement with ReCor Medical Inc. together with an additional investment. As part of the agreement, Otsuka Holdings.   obtained exclusive rights to the commercialization...

Visionary, up to $2 billion multi-year alliance to focus on development of new gene therapy and gene editing technologies and create a therapeutic platform for a broad range of diseases Biogen to team up with renowned gene therapy...

Chugai Pharmaceutical Co Ltd announced that its co-sponsorship of “Relay for Life Japan” (Organizer: Japan Cancer Society etc.), a charity activity aiming to support cancer patients and their families, and encourage the entire community to confront and conquer cancer...

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies,...

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe.   ]The two...

First Fc Fusion Therapy Approved for haemophilia B in the EU to Provide Extended Protection Against Bleeds Swedish Orphan Biovitrum AB and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life...